Mesoblast Ltd

MESO Nasdaq SEC CIK 1345099
Follow Mesoblast Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2026 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$17.2M−$102.1M
FY24$5.9M−$88M
FY23$7.5M−$81.9M
FY22$10.2M−$91.3M
FY21$7.4M−$98.8M
FY20$32.2M−$77.9M
FY19$16.7M−$89.8M
FY18$17.3M−$35.3M
FY17$2.4M−$76.8M
FY16$42.5M−$4.1M
FY15--
MarginsShare of revenue
  • Gross margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginNet margin
FY2570.2%−593.9%
FY24100%−1490.3%
FY23100%−1091.7%
FY22-−894.6%
FY21-−1329.2%
FY20-−242.4%
FY19-−537%
FY18-−203.5%
FY17-−3184.7%
FY16-−9.7%
FY15--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$50.6M
FY24−$48.7M
FY23−$63.5M
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Mesoblast
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearMesoblastHealthcare median
FY25−593.9%−30.6%
FY24−1490.3%−47%
FY23−1091.7%−58%
FY22−894.6%−80.4%
FY21−1329.2%−71.9%
FY20−242.4%−62.2%
FY19−537%−46.3%
FY18−203.5%−49.6%
FY17−3184.7%−45.9%
FY16−9.7%−36%
FY15-−38.4%